Health Canada Approves Use of Pfizer-BioNTech COVID-19 Vaccine for Canadians 12 and Over
On May 5, 2021, Health Canada approved the use of Pfizer-BioNTech mRNA vaccine in children ages 12 to 15, after initially authorizing its use for individuals 16 and older. This would be the first COVID-19 vaccine authorized for use in children in Canada.
Health Canada approval was based on topline results from a Phase 3 clinical trial in the United States which involved 2,260 adolescents from 12 to 15 years old. The trial demonstrated the vaccine is 100% effective in preventing SARS-CoV-2 infection in this age group beginning 1 week after the second dose. The vaccine was well tolerated among trial participants and there were no major safety concerns identified.
Subscribe to the latest MS research news by email by entering your info below: